Trial
NCT03498716
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
Breast International Group; Alliance Foundation Trials, LLC.; Jules Bordet Institute; Frontier Science & Technology Research Foundation, Inc.
Condition
Triple Negative Breast Cancer
Intervention
Atezolizumab
Why stopped
The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-21